Aldeyra Therapeutics
ALDX
130 hedge funds and large institutions have $204M invested in Aldeyra Therapeutics in 2025 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 57 increasing their positions, 25 reducing their positions, and 15 closing their positions.
610% more call options, than puts
Call options by funds: $2.89M | Put options by funds: $407K
128% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 25
60% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 15
56% more capital invested
Capital invested by funds: $131M → $204M (+$73.4M)
8.35% more ownership
Funds ownership: 56.97% → 65.33% (+8.4%)
7% more funds holding
Funds holding: 121 → 130 (+9)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| 1 |
PA
Perceptive Advisors
New York
|
+$6.1M |
| 2 |
D.E. Shaw & Co
New York
|
+$4.65M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$3.36M |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$2.22M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.74M |
Top Sellers
| 1 |
6CM
683 Capital Management
New York
|
-$1.36M |
| 2 |
PI
PFG Investments
Woodbury,
New York
|
-$998K |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$957K |
| 4 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
-$782K |
| 5 |
Walleye Capital
New York
|
-$596K |
ALDX Hedge Fund Activity: Q3 2025 in Review
130 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q3 2025, worth a combined $204M — up 56% from $131M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new ALDX positions and 15 closed out — a net gain of 9 holders — while 57 added to existing stakes and 25 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $6.1M. The largest seller was 683 Capital Management, cutting an estimated $1.36M.
- 130 institutional investors held Aldeyra Therapeutics (ALDX) as of Q3 2025, up from 121 in Q2 2025.
- Funds reported $204M of Aldeyra Therapeutics stock for Q3 2025, up 56% quarter-over-quarter.
- 24 funds opened new Aldeyra Therapeutics positions in Q3 2025 and 15 closed out, a net change of +9 holders.
- The largest Aldeyra Therapeutics buyer in Q3 2025 was Perceptive Advisors, an estimated $6.1M added.
- The largest Aldeyra Therapeutics seller in Q3 2025 was 683 Capital Management, an estimated $1.36M sold.
Based on aggregated 13F filings for Q3 2025.